On March 3, 2010
The Incompetent Monopolist: Genzyme’s Drug Screwups Invite Attacks by Shire, Pfizer
The FDA approved Shire (SHPGY)’s Gaucher disease drug, Vpriv, on Feb. 27, allowing the U.K. company to begin its planned destruction of Genzyme (GENZ)’s monopoly of the category. Genzyme is currently hobbled by its own incompetence and cannot produce its
…
0 Comments